Analysts: Stallergenes' approval may expand the market for allergy tablets
The fact that French company Stallergenes Greer can now also provide a tablet treatment for dust mite allergies in several European markets may ultimately benefit ALK, according to two analysts.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Carnegie Investment Bank Equity Analyst Jesper Ilsøe notes that the US Food and Drug Administration approval of Stallergenes Greer's tablet for dust mite allergies may lead to a further expansion of the market for treating allergies with tablets, which is currently relatively small.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Food allergy venture to boost ALK's growth
For subscribers
ALK expands digital venture with US partnership
For subscribers
